Danaher Corporation (ETR: DAP)
Germany
· Delayed Price · Currency is EUR | Market Cap | 167.29B |
| Revenue (ttm) | 21.27B |
| Net Income (ttm) | 3.49B |
| Shares Out | n/a |
| EPS (ttm) | 4.70 |
| PE Ratio | 47.99 |
| Forward PE | n/a |
| Dividend | 1.00 (0.43%) |
| Ex-Dividend Date | Dec 27, 2024 |
| Volume | 659 |
| Average Volume | 467 |
| Open | 235.20 |
| Previous Close | 231.65 |
| Day's Range | 233.30 - 235.30 |
| 52-Week Range | 205.00 - 260.00 |
| Beta | 0.88 |
| RSI | 51.11 |
| Earnings Date | Jan 28, 2025 |
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and service... [Read more]
Financial Performance
In 2023, Danaher's revenue was $23.89 billion, a decrease of -10.33% compared to the previous year's $26.64 billion. Earnings were $4.74 billion, a decrease of -33.23%.
Financial numbers in USD Financial StatementsNews
Danaher: Transition Year Recap
The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems
In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable di...
Danaher Corp (DHR) Unveils Advanced RUO Assays for Neurodegenerative Disease Research
Danaher Corp (DHR) Unveils Advanced RUO Assays for Neurodegenerative Disease Research
Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research
New, Fully Automated, High-Throughput RUO Assays offered on Beckman Coulter Immunoassay Analyzers BREA, Calif. , Jan. 15, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in advanced ...
Danaher Corporation: Question Mark Behind The Moat And Probably Overvalued
Danaher Corporation (DHR) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Danaher expects low-single digit percent revenue growth in Q4
Danaher CEO to Comment on Financial Performance
WASHINGTON , Jan. 13, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Compa...
Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth
Seeking Alpha's Quant Valuation and Growth Grades identify 6 blue-chip stocks with extremely high valuations matched against limited operating growth potential. Costco, Cencora, West Pharmaceutical Se...
Invest with Confidence: Intrinsic Value Unveiled of Danaher Corp
Invest with Confidence: Intrinsic Value Unveiled of Danaher Corp
Danaher Announces Investment Partnership in Innovaccer Inc.
Partnership seeks to improve patient outcomes and experience through novel digital and diagnostic solutions. Investment aligns with Danaher's mission to accelerate the transition to precision medicine...
Danaher to Present at J.P. Morgan Healthcare Conference
WASHINGTON , Jan. 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.
Danaher: A Wide-Moat Gem I Cannot Buy Enough Of
Discover why Danaher is a strong investment choice with its wide moat business model, M&A strategy, and growth potential for total return investors.
Danaher Schedules Fourth Quarter 2024 Earnings Conference Call
WASHINGTON , Jan. 2, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2024 on Wednesday, January 29, 20...
Danaher had a disappointing 2024. Its path to success next year goes through Wall Street
A pickup in the initial public offering market would be a boon to Danaher.
Beyond Market Price: Uncovering Danaher Corp's Intrinsic Value
Beyond Market Price: Uncovering Danaher Corp's Intrinsic Value
Here's How Much You Would Have Made Owning Danaher Stock In The Last 10 Years
Danaher (NYSE: DHR) has outperformed the market over the past 10 years by 3.64% on an annualized basis producing an average annual return of 14.74%. Currently, Danaher has a market capitalization of ...
Analysts' Top S&P 500 Stocks to Buy Now
Nvidia and Amazon.com lead the list of stocks scoring rare Strong Buy consensus ratings this month, but Micron Technologies fell off.
Danaher, Cryoport, Sartorius win Buy as Guggenheim expands bioprocessing coverage
3 of the Best Companies to Own in 2025 and Beyond
#Morningstar #BestStockstoInvestIn #StockInvesting These companies have durable competitive advantages and generate reliable cash flows. 00:00 Introduction 00:46 Danaher DHR 01:36 Paychex PAYX 02:17 ...
Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value
Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "M...
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst
BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024.
Danaher Corp (DHR) Announces Quarterly Dividend
Danaher Corp (DHR) Announces Quarterly Dividend
Danaher Announces Quarterly Dividend
WASHINGTON , Dec. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common s...